NCT06960395 2026-03-17
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Vir Biotechnology, Inc.
Phase 1 Recruiting
Vir Biotechnology, Inc.
Kumquat Biosciences Inc.
Kumquat Biosciences Inc.
GeneSail Biotech (Shanghai) Co., Ltd.
Heronova Pharmaceuticals
GrandPharma (China) Co., Ltd.
Novartis
Weill Medical College of Cornell University